Web5 apr. 2024 · prospective clinical data-set of 928 18-years or older DLBCL patients, with a centralized gene expression profiling and pathological review, eligible for anthracycline-based treatment; 2) 30 months Progression-Free Survival (PFS) in line with the best results of the recent phase 3 trials on http://mdedge.ma1.medscape.com/hematology-oncology/article/247607/dlbcl/improving-dlbcl-outcomes-single-agent-regimens-fall-short
Pattern of failure and optimal treatment strategy for primary
Web10 sep. 2024 · Second-Line Therapy With Goal of ASCT Second-line therapy followed by high-dose therapy with ASCT is the backbone of treatment for relapsed/refractory … Web13 apr. 2024 · The trial, in diffuse large B-cell lymphoma (DLBCL), was based on the premise that many initially responding patients relapse owing to T-cell exhaustion. PD- (L)1 blockade, such as Merck & Co’s Keytruda, “is sometimes administered with the hope that it will reverse T-cell exhaustion following Car-T cell therapy”, the authors wrote. christmas all the way
Polatuzumab Vedotin Plus RICE for Relapsed/Refractory DLBCL
Web9 jan. 2024 · After doctors diagnose diffuse large B-cell lymphoma (DLBCL), they’ll do more tests to find out where the cancer is in your body and how far it has spread. This process … Web2 nov. 2024 · DLBCL is a fast-growing, aggressive form of NHL. DLBCL is fatal if left untreated, but with timely and appropriate treatment, approximately two-thirds of all … Web6 apr. 2024 · rPFS was longer in the combination arm with median rPFS of 21.3 months for enzalutamide versus 24.3 months for enzalutamide plus abiraterone acetate and prednisone (HR 0.86; two-sided p = 0.02). However, pharmacokinetic clearance of abiraterone acetate was 2.2- to 2.9-fold higher when administered with enzalutamide, compared with … christmas allusions